Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pia Bader

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
BJU International|March 12, 2011
Is there a prostate-specific antigen upper limit for radical prostatectomy?Paulo Gontero, Martin Spahn, Bertrand Tombal, et al.
European Urology|March 20, 2010
Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patientsMartin Spahn, Steven Joniau, Paolo Gontero, et al.
European Urology|February 4, 2014
Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional studySteven Joniau, Alberto Briganti, Paolo Gontero, et al.
European Urology|April 2, 2014
Pretreatment tables predicting pathologic stage of locally advanced prostate cancerSteven Joniau, Martin Spahn, Alberto Briganti, et al.
Science Advances|March 10, 2023
Spectral imaging enables contrast agent-free real-time ischemia monitoring in laparoscopic surgeryLeonardo Ayala, Tim J Adler, Silvia Seidlitz, et al.
Advances in Urology|March 9, 2012
The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysisMaria Schubert, Steven Joniau, Paolo Gontero, et al.
Therapeutic Advances in Medical Oncology|April 7, 2022
Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based studyKlaus-Peter Dieckmann, Tomas Pokrivcak, Lajos Geczi, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
BJU International|March 12, 2011
Is there a prostate-specific antigen upper limit for radical prostatectomy?Paulo Gontero, Martin Spahn, Bertrand Tombal, et al.
European Urology|March 20, 2010
Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patientsMartin Spahn, Steven Joniau, Paolo Gontero, et al.
European Urology|February 4, 2014
Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional studySteven Joniau, Alberto Briganti, Paolo Gontero, et al.
European Urology|April 2, 2014
Pretreatment tables predicting pathologic stage of locally advanced prostate cancerSteven Joniau, Martin Spahn, Alberto Briganti, et al.
Science Advances|March 10, 2023
Spectral imaging enables contrast agent-free real-time ischemia monitoring in laparoscopic surgeryLeonardo Ayala, Tim J Adler, Silvia Seidlitz, et al.
Advances in Urology|March 9, 2012
The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysisMaria Schubert, Steven Joniau, Paolo Gontero, et al.
Therapeutic Advances in Medical Oncology|April 7, 2022
Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based studyKlaus-Peter Dieckmann, Tomas Pokrivcak, Lajos Geczi, et al.
Pageof 2